Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Darr

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Virchows Archiv : an International Journal of Pathology|December 9, 2024
High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trialOliver Hommerding, Marit Bernhardt, Tobias Kreft, et al.
Plos One|December 1, 2023
Prediction models of incontinence and sexual function one year after radical prostatectomy based on data from 20 164 prostate cancer patientsNora Tabea Sibert, Tobias Kurth, Clara Breidenbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin ResistanceNiklas Klümper, Damian J Ralser, Jörg Ellinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2024
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial CancerNiklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Virchows Archiv : an International Journal of Pathology|December 9, 2024
High interobserver variability of PTEN immunohistochemistry defining PTEN status in low- to intermediate-risk prostate cancer: results of the first German ring trialOliver Hommerding, Marit Bernhardt, Tobias Kreft, et al.
Plos One|December 1, 2023
Prediction models of incontinence and sexual function one year after radical prostatectomy based on data from 20 164 prostate cancer patientsNora Tabea Sibert, Tobias Kurth, Clara Breidenbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin ResistanceNiklas Klümper, Damian J Ralser, Jörg Ellinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2024
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial CancerNiklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, et al.
Pageof 7